Organisation paid for research Program year 2025 Source: CMS Open Payments

Cincy Science

Neither a doctor nor a teaching hospital

Research payments

$36,711

8 payments

Through program year 2025, Cincy Science is reported as receiving $36,711 in research payments, across 8 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $24,477 5
2024 Research $5,910 2
2020 Research $6,324 1

Breakdown

Who paid Research payments · program years 2020–2025
  1. E.R. Squibb & Sons, L.L.C. $27,089 3 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $6,324 1 payment
  3. AbbVie, Inc. $3,298 4 payments
Studies the money was for Research payments · program years 2020–2025
  1. An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in De Novo Subjects With DSM-5 Schizophrenia $27,089 3 payments
  2. Safety and Tolerability Study of Shp465 in Children Aged 4 to 12 Years Diagnosed With Attention-Deficit/Hyperactivity Disorder (Adhd) $6,324 1 payment
  3. A 52-Week, Multicenter, Open-Label, Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Subjects with Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder $1,558 1 payment
  4. A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17) $1,440 1 payment
  5. A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 Years of Age. $150 1 payment
  6. A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Atogepant in Pediatric Subjects 6 to 17 years of age with Migraine $150 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record